Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Uricosuric Agents"" wg kryterium: Temat


Tytuł :
The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study.
Autorzy :
Choi ST; Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Song JS; Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Kim SJ; Division of Nephrology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University, Incheon, Korea.
Kim CH; Division of Nephrology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University, Incheon, Korea.
Moon SJ; Division of Nephrology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University, Incheon, Korea. .
Pokaż więcej
Źródło :
Journal of Korean medical science [J Korean Med Sci] 2020 Apr 06; Vol. 35 (13), pp. e95. Date of Electronic Publication: 2020 Apr 06.
Typ publikacji :
Journal Article
MeSH Terms :
Creatinine*/urine
Gout*/drug therapy
Uric Acid*/urine
Uricosuric Agents*/therapeutic use
Adult ; Aged ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Autorzy :
Fukase H; Clinical Research Hospital Tokyo, NT-Building Level 3, 3-87-4, Hara-machi, Shinjuku-ku, Tokyo, 162-0053, Japan.
Okui D; Medical R&D Division, Development Department, Fuji Yakuhin Co., Ltd., 4-383, Sakuragi-cho, Omiya-ku, Saitama-shi, Saitama, 330-9508, Japan. .
Sasaki T; Medical R&D Division, Development Department, Fuji Yakuhin Co., Ltd., 4-383, Sakuragi-cho, Omiya-ku, Saitama-shi, Saitama, 330-9508, Japan.
Fushimi M; Medical R&D Division, Development Department, Fuji Yakuhin Co., Ltd., 4-383, Sakuragi-cho, Omiya-ku, Saitama-shi, Saitama, 330-9508, Japan.
Ohashi T; Medical R&D Division, Development Department, Fuji Yakuhin Co., Ltd., 4-383, Sakuragi-cho, Omiya-ku, Saitama-shi, Saitama, 330-9508, Japan.
Hosoya T; Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan.
Pokaż więcej
Źródło :
Clinical and experimental nephrology [Clin Exp Nephrol] 2020 Mar; Vol. 24 (Suppl 1), pp. 17-24. Date of Electronic Publication: 2019 Dec 10.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Uricosuric Agents*
Benzothiazoles/*adverse effects
Benzothiazoles/*pharmacokinetics
Renal Insufficiency/*physiopathology
Adult ; Aged ; Benzothiazoles/pharmacology ; Glomerular Filtration Rate ; Humans ; Male ; Middle Aged ; Uric Acid/blood ; Uric Acid/urine
Czasopismo naukowe
Tytuł :
[Pharmacological properties and clinical efficacy of dotinurad (URECE tablets), a novel hypouricemic agent].
Autorzy :
Taniguchi T; Biological Research Department, FUJI YAKUHIN CO., LTD.
Ashizawa N; Biological Research Department, FUJI YAKUHIN CO., LTD.
Pokaż więcej
Źródło :
Nihon yakurigaku zasshi. Folia pharmacologica Japonica [Nihon Yakurigaku Zasshi] 2020; Vol. 155 (6), pp. 426-434.
Typ publikacji :
Journal Article
MeSH Terms :
Hyperuricemia*/drug therapy
Organic Anion Transporters*
Uricosuric Agents*
Humans ; Japan ; Philippines ; Tablets ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Autorzy :
Fitz-Patrick D; East-West Medical Research Institute, Honolulu, HI, USA.
Roberson K; Delta Waves Sleep Disorder & Research Center, Colorado Springs, CO, USA.
Niwa K; Niwa Family Clinic, Chofu, Tokyo, Japan.
Fujimura T; Thinkpark Heart Clinic, Tokyo, Japan.
Mori K; Mori Clinic, Fukuoka, Japan.
Hall J; Ardea Biosciences, Inc., San Diego, CA, USA.
Yan X; Ardea Biosciences, Inc., San Diego, CA, USA.
Shen Z; Ardea Biosciences, Inc., San Diego, CA, USA.
Liu S; Ardea Biosciences, Inc., San Diego, CA, USA.
Ito Y; Ardea Biosciences, Inc., San Diego, CA, USA.
Baumgartner S; Ardea Biosciences, Inc., San Diego, CA, USA.
Pokaż więcej
Źródło :
Modern rheumatology [Mod Rheumatol] 2019 Nov; Vol. 29 (6), pp. 1042-1052. Date of Electronic Publication: 2018 Dec 12.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Gout/*drug therapy
Gout Suppressants/*adverse effects
Hyperuricemia/*drug therapy
Naphthalenes/*adverse effects
Propionates/*adverse effects
Pyridines/*adverse effects
Uricosuric Agents/*adverse effects
Adult ; Female ; Gout Suppressants/therapeutic use ; Humans ; Japan ; Male ; Middle Aged ; Naphthalenes/therapeutic use ; Propionates/therapeutic use ; Pyridines/therapeutic use ; United States ; Uricosuric Agents/therapeutic use
Czasopismo naukowe
Tytuł :
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Autorzy :
Lee HA; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea.; Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
Yu KS; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea.
Park SI; Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Korea.; East-West Medical Research Institute, Kyung Hee University, Seoul, Korea.
Yoon S; Clinical Trials Center, Seoul National University Bundang Hospital, Kyeonggido, Korea.
Onohara M; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
Ahn Y; JW Pharmaceutical Corporation, Seoul, Korea.
Lee H; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea.; Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
Pokaż więcej
Źródło :
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2019 Nov 01; Vol. 58 (11), pp. 1976-1984.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Hydrocarbons, Brominated/*pharmacology
Organic Anion Transporters/*antagonists & inhibitors
Organic Cation Transport Proteins/*antagonists & inhibitors
Uric Acid/*blood
Uricosuric Agents/*pharmacology
Administration, Oral ; Adult ; Asian Continental Ancestry Group ; Double-Blind Method ; European Continental Ancestry Group ; Gout/blood ; Gout/drug therapy ; Healthy Volunteers ; Humans ; Hydrocarbons, Brominated/administration & dosage ; Hyperuricemia/blood ; Hyperuricemia/drug therapy ; Male ; Uricosuric Agents/administration & dosage
Czasopismo naukowe
Tytuł :
Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Autorzy :
Taniguchi T; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.) .
Ashizawa N; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Matsumoto K; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Saito R; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Motoki K; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Sakai M; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Chikamatsu N; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Hagihara C; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Hashiba M; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Iwanaga T; Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi Ward, Saitama City, Saitama, Japan (T.T., N.A., K.Ma., K.Mo., M.S., N.C., C.H., T.I.) and Research Center, Mochida Pharmaceutical Co., Ltd., Jimba, Gotemba City, Shizuoka, Japan (R.S., M.H.).
Pokaż więcej
Źródło :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2019 Oct; Vol. 371 (1), pp. 162-170. Date of Electronic Publication: 2019 Aug 01.
Typ publikacji :
Journal Article
MeSH Terms :
Benzothiazoles/*pharmacology
Uricosuric Agents/*pharmacokinetics
ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors ; ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism ; Animals ; Benzothiazoles/adverse effects ; Benzothiazoles/pharmacokinetics ; Drug Evaluation, Preclinical ; HEK293 Cells ; Haplorhini ; Humans ; Male ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/metabolism ; Organic Anion Transport Protein 1/antagonists & inhibitors ; Organic Anion Transport Protein 1/metabolism ; Organic Anion Transporters/antagonists & inhibitors ; Organic Anion Transporters/metabolism ; Organic Anion Transporters, Sodium-Independent/antagonists & inhibitors ; Organic Anion Transporters, Sodium-Independent/metabolism ; Organic Cation Transport Proteins/antagonists & inhibitors ; Organic Cation Transport Proteins/metabolism ; Protein Binding ; Rats ; Rats, Sprague-Dawley ; Uric Acid/blood ; Uric Acid/urine ; Uricosuric Agents/adverse effects
Czasopismo naukowe
Tytuł :
Benzbromarone in the treatment of gout.
Autorzy :
Azevedo VF; Universidade Federal do Paraná, Rua General Carneiro 181, Centro, Curitiba, Paraná, Brazil. .; Edumed Educação em Saúde, Rua Bispo Dom José, 2495, Curitiba, Paraná, Brazil. .
Kos IA; Edumed Educação em Saúde, Rua Bispo Dom José, 2495, Curitiba, Paraná, Brazil.
Vargas-Santos AB; Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil.
da Rocha Castelar Pinheiro G; Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil.
Dos Santos Paiva E; Universidade Federal do Paraná, Rua General Carneiro 181, Centro, Curitiba, Paraná, Brazil.
Pokaż więcej
Źródło :
Advances in rheumatology (London, England) [Adv Rheumatol] 2019 Aug 07; Vol. 59 (1), pp. 37. Date of Electronic Publication: 2019 Aug 07.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Benzbromarone/*therapeutic use
Gout/*drug therapy
Uricosuric Agents/*therapeutic use
Benzbromarone/adverse effects ; Benzbromarone/metabolism ; Cytochrome P-450 CYP2C9/metabolism ; Humans ; In Vitro Techniques ; Liver/drug effects ; Liver/metabolism ; Mitochondria, Liver/drug effects ; Models, Animal ; Organic Anion Transporters/antagonists & inhibitors ; Organic Cation Transport Proteins/antagonists & inhibitors ; Safety-Based Drug Withdrawals ; Symptom Flare Up ; Uricosuric Agents/adverse effects ; Uricosuric Agents/metabolism
Czasopismo naukowe
Tytuł :
Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Autorzy :
Nakata T; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.; Department of Cardiology, Saiseikai Nagasaki Hospital.
Ikeda S; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Koga S; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Yonekura T; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Tsuneto A; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Doi Y; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Fukae S; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Minami T; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Kawano H; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Maemura K; Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Pokaż więcej
Źródło :
International heart journal [Int Heart J] 2020 Sep 29; Vol. 61 (5), pp. 984-992. Date of Electronic Publication: 2020 Sep 12.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Benzbromarone/*therapeutic use
Endothelium, Vascular/*physiopathology
Febuxostat/*therapeutic use
Hyperemia/*physiopathology
Hyperuricemia/*drug therapy
Uricosuric Agents/*therapeutic use
Adiponectin/blood ; Aged ; Arginine/analogs & derivatives ; Arginine/blood ; Cross-Over Studies ; Female ; Gout Suppressants/therapeutic use ; Humans ; Hyperuricemia/physiopathology ; Male ; Middle Aged ; Organic Anion Transporters/antagonists & inhibitors ; Organic Cation Transport Proteins/antagonists & inhibitors ; Treatment Outcome ; Uric Acid/blood ; Xanthine Oxidase/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Pharmacotherapy for hyperuricaemia in hypertensive patients.
Autorzy :
Gois PHF; Department of Nephrology, Royal Brisbane and Women's Hospital, Herston, Australia.
Souza ERM; Nephrology, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Sep 02; Vol. 9. Cochrane AN: CD008652. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Allopurinol/*therapeutic use
Hypertension/*drug therapy
Hyperuricemia/*drug therapy
Uricosuric Agents/*therapeutic use
Adolescent ; Adult ; Blood Pressure/drug effects ; Child ; Humans ; Hypertension/complications ; Hyperuricemia/complications ; Patient Dropouts/statistics & numerical data ; Placebos/therapeutic use ; Prehypertension/drug therapy ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis.
Autorzy :
Zhu J; aDepartment of Orthopaedics, Xiangya Hospital, Central South University bHunan Key Laboratory of Joint Degeneration and Injury cDepartment of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
Wang Y
Chen Y
Li X
Yang Z
Li H
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Aug 14; Vol. 99 (33), pp. e21610.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Gout/*epidemiology
Hyperuricemia/*epidemiology
Osteoarthritis/*epidemiology
Uric Acid/*blood
Uricosuric Agents/*administration & dosage
Gout/drug therapy ; Gout/prevention & control ; Humans ; Hyperuricemia/drug therapy ; Hyperuricemia/prevention & control ; Observational Studies as Topic ; Osteoarthritis/drug therapy ; Osteoarthritis/prevention & control ; Research Design
Czasopismo naukowe
Tytuł :
Comparative Study of Real-Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics.
Autorzy :
Te Kampe R; Maastricht University Medical Centre, Maastricht, The Netherlands.
van Durme C; Maastricht University Medical Centre, Maastricht, The Netherlands.
Janssen M; VieCuri Medical Centre, Venlo, The Netherlands.
van Eijk-Hustings Y; Maastricht University Medical Centre, Maastricht, The Netherlands.
Boonen A; Maastricht University Medical Centre, Maastricht, The Netherlands.
Jansen TL; VieCuri Medical Centre, Venlo, The Netherlands.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2020 Aug; Vol. 72 (8), pp. 1169-1176. Date of Electronic Publication: 2020 Jun 11.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Clinical Decision Rules*
Gout/*therapy
Gout Suppressants/*therapeutic use
Precision Medicine/*statistics & numerical data
Uric Acid/*blood
Aged ; Allopurinol/therapeutic use ; Clinical Protocols ; Female ; Follow-Up Studies ; Gout/blood ; Humans ; Logistic Models ; Male ; Middle Aged ; Patient Satisfaction ; Precision Medicine/methods ; Symptom Flare Up ; Treatment Outcome ; Uricosuric Agents/therapeutic use
Czasopismo naukowe
Tytuł :
Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
Autorzy :
Sultan AA; Arthritis Research UK Primary Care Centre (Abdul Sultan, Muller, Whittle, Roddy, Mallen, Clarson), Research Institute for Primary Care & Health Sciences, Keele University, UK; Haywood Academic Rheumatology Centre (Roddy), Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK .
Muller S; Arthritis Research UK Primary Care Centre (Abdul Sultan, Muller, Whittle, Roddy, Mallen, Clarson), Research Institute for Primary Care & Health Sciences, Keele University, UK; Haywood Academic Rheumatology Centre (Roddy), Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK.
Whittle R; Arthritis Research UK Primary Care Centre (Abdul Sultan, Muller, Whittle, Roddy, Mallen, Clarson), Research Institute for Primary Care & Health Sciences, Keele University, UK; Haywood Academic Rheumatology Centre (Roddy), Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK.
Roddy E; Arthritis Research UK Primary Care Centre (Abdul Sultan, Muller, Whittle, Roddy, Mallen, Clarson), Research Institute for Primary Care & Health Sciences, Keele University, UK; Haywood Academic Rheumatology Centre (Roddy), Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK.
Mallen C; Arthritis Research UK Primary Care Centre (Abdul Sultan, Muller, Whittle, Roddy, Mallen, Clarson), Research Institute for Primary Care & Health Sciences, Keele University, UK; Haywood Academic Rheumatology Centre (Roddy), Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK.
Clarson L; Arthritis Research UK Primary Care Centre (Abdul Sultan, Muller, Whittle, Roddy, Mallen, Clarson), Research Institute for Primary Care & Health Sciences, Keele University, UK; Haywood Academic Rheumatology Centre (Roddy), Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK.
Pokaż więcej
Źródło :
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne [CMAJ] 2019 Jun 03; Vol. 191 (22), pp. E597-E603.
Typ publikacji :
Journal Article
MeSH Terms :
Gout/*complications
Gout/*drug therapy
Gout Suppressants/*adverse effects
Hospitalization/*statistics & numerical data
Uric Acid/*metabolism
Uricosuric Agents/*adverse effects
Venous Thromboembolism/*etiology
Aged ; Case-Control Studies ; Female ; Gout/physiopathology ; Gout Suppressants/therapeutic use ; Humans ; Length of Stay ; Male ; Middle Aged ; Risk Factors ; Uricosuric Agents/therapeutic use ; Venous Thromboembolism/blood
Czasopismo naukowe
Tytuł :
Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.
Autorzy :
Ye X; Department of Pharmacy, Zhejiang Provincial People's Hospital.; Department of Pharmacy, People's Hospital of Hangzhou Medical College, Hangzhou.; Department of Pharmacy, China-Japan Friendship Hospital, Beijing.
Wu J; Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, Jiangsu.
Tang K; Department of Pharmacy, China-Japan Friendship Hospital, Beijing.
Li W; Department of Nephrology, China-Japan Friendship Hospital, Beijing.
Xiong C; College of Pharmacy, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, China.
Zhuo L; Department of Nephrology, China-Japan Friendship Hospital, Beijing.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2019 Apr; Vol. 98 (15), pp. e15214.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Acute Kidney Injury/*etiology
Benzbromarone/*adverse effects
Hyperuricemia/*drug therapy
Uricosuric Agents/*adverse effects
Urolithiasis/*drug therapy
Acute Kidney Injury/pathology ; Adolescent ; Benzbromarone/therapeutic use ; Humans ; Hyperuricemia/complications ; Kidney/drug effects ; Kidney/pathology ; Male ; Middle Aged ; Self Medication/adverse effects ; Uricosuric Agents/therapeutic use ; Urolithiasis/complications
Czasopismo naukowe
Tytuł :
Safety and tolerability of available urate-lowering drugs: a critical review.
Autorzy :
Strilchuk L; a Department of Therapy and Medical Diagnostics , Lviv National Medical University , Lviv , Ukraine.
Fogacci F; b Medical and Surgical Sciences Department , Alma Mater Studiorum University of Bologna , Bologna , Italy.
Cicero AF; b Medical and Surgical Sciences Department , Alma Mater Studiorum University of Bologna , Bologna , Italy.; c Medical and Surgical Sciences Department , Sant'Orsola-Malpighi University Hospital , Bologna , Italy.
Pokaż więcej
Źródło :
Expert opinion on drug safety [Expert Opin Drug Saf] 2019 Apr; Vol. 18 (4), pp. 261-271. Date of Electronic Publication: 2019 Mar 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Gout Suppressants/*pharmacology
Uric Acid/*metabolism
Uricosuric Agents/*pharmacology
Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacology ; Gout/drug therapy ; Gout Suppressants/adverse effects ; Humans ; Uricosuric Agents/adverse effects ; Xanthine Oxidase/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
Autorzy :
Yang C; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Zhou D; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Shen Z; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Wilson DM; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Renner M; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Miner JN; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Girardet JL; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California.
Lee CA; Preclinical and Clinical DMPK (C.Y., Z.S., C.A.L.), Bioanalytical (D.Z., D.M.W.), Biology (J.N.M.), and Chemistry (M.R., J.-L.G.) Departments, Ardea Biosciences, Inc., San Diego, California .
Pokaż więcej
Źródło :
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2019 Feb; Vol. 47 (2), pp. 104-113. Date of Electronic Publication: 2018 Nov 15.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Organic Anion Transporters/*antagonists & inhibitors
Organic Cation Transport Proteins/*antagonists & inhibitors
Renal Reabsorption/*drug effects
Thioglycolates/*pharmacology
Triazoles/*pharmacology
Uric Acid/*metabolism
Uricosuric Agents/*pharmacology
Administration, Oral ; Adult ; Gout/drug therapy ; HEK293 Cells ; Healthy Volunteers ; Humans ; Kidney/drug effects ; Kidney/metabolism ; Male ; Microsomes, Liver ; Middle Aged ; Organic Anion Transporters/metabolism ; Organic Anion Transporters, Sodium-Independent/antagonists & inhibitors ; Organic Anion Transporters, Sodium-Independent/metabolism ; Organic Cation Transport Proteins/metabolism ; Stereoisomerism ; Structure-Activity Relationship ; Thioglycolates/chemistry ; Thioglycolates/metabolism ; Thioglycolates/therapeutic use ; Triazoles/chemistry ; Triazoles/metabolism ; Triazoles/therapeutic use ; Uric Acid/blood ; Uric Acid/urine ; Uricosuric Agents/chemistry ; Uricosuric Agents/metabolism ; Uricosuric Agents/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.
Autorzy :
Ohe T; Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan. Electronic address: .
Umezawa R; Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan.
Kitagawara Y; Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan.
Yasuda D; Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan.
Takahashi K; Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan.
Nakamura S; Department of Chemistry, Nippon Medical School, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo, Japan.
Abe A; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan.
Sekine S; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan.
Ito K; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan.
Okunushi K; Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
Morio H; Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
Furihata T; Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
Anzai N; Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
Mashino T; Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 Dec 15; Vol. 28 (23-24), pp. 3708-3711. Date of Electronic Publication: 2018 Oct 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Benzbromarone/*analogs & derivatives
Benzbromarone/*metabolism
Organic Anion Transporters/*antagonists & inhibitors
Organic Cation Transport Proteins/*antagonists & inhibitors
Uricosuric Agents/*chemistry
Uricosuric Agents/*metabolism
Activation, Metabolic ; Animals ; Benzbromarone/pharmacology ; Benzbromarone/toxicity ; Chemistry Techniques, Synthetic ; HEK293 Cells ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Humans ; Mice ; Microsomes, Liver/drug effects ; Microsomes, Liver/metabolism ; Mitochondria/drug effects ; Mitochondria/metabolism ; Organic Anion Transporters/metabolism ; Organic Cation Transport Proteins/metabolism ; Rats ; Uric Acid/metabolism ; Uricosuric Agents/pharmacology ; Uricosuric Agents/toxicity
Czasopismo naukowe
Tytuł :
The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS.
Autorzy :
Zhou D; Bioanalytical Department, Ardea Biosciences / AstraZeneca, San Diego, CA, United States.
Sun L; Bioanalytical Department, Ardea Biosciences / AstraZeneca, San Diego, CA, United States.
Nguyen M; Bioanalytical Department, Ardea Biosciences / AstraZeneca, San Diego, CA, United States.
Yeh LT; Bioanalytical Department, Ardea Biosciences / AstraZeneca, San Diego, CA, United States.
Wilson DM; Bioanalytical Department, Ardea Biosciences / AstraZeneca, San Diego, CA, United States.
Pokaż więcej
Źródło :
Drug metabolism letters [Drug Metab Lett] 2019; Vol. 13 (2), pp. 111-122.
Typ publikacji :
Journal Article; Validation Study
MeSH Terms :
Hepatic Insufficiency/*metabolism
Renal Insufficiency/*metabolism
Thioglycolates/*blood
Triazoles/*blood
Uricosuric Agents/*blood
Allopurinol/pharmacokinetics ; Calibration ; Chromatography, High Pressure Liquid/methods ; Chromatography, High Pressure Liquid/standards ; Clinical Trials as Topic ; Hepatic Insufficiency/blood ; Hepatic Insufficiency/physiopathology ; Humans ; Kidney/metabolism ; Kidney/physiopathology ; Liver/metabolism ; Liver/physiopathology ; Oxypurinol/blood ; Oxypurinol/pharmacokinetics ; Reference Standards ; Renal Insufficiency/blood ; Renal Insufficiency/physiopathology ; Renal Reabsorption ; Reproducibility of Results ; Tandem Mass Spectrometry/methods ; Tandem Mass Spectrometry/standards ; Thioglycolates/pharmacokinetics ; Triazoles/pharmacokinetics ; Uricosuric Agents/pharmacokinetics ; Verapamil/blood ; Verapamil/pharmacokinetics
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Autorzy :
Wu JY; Department of Family Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
Chang YT; School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Lin YC; Department of Family Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.; Department of Family Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Lee CH; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Comprehensive Cancer Center of Taipei Medical University, Taipei, Taiwan.; Department of Laboratory Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
Loh EW; Center for Evidence-Based Health Care, Department of Medical Research, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
Wu MY; Center for Evidence-Based Health Care, Department of Medical Research, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.; Division of Nephrology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chang YS; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
Tam KW; Center for Evidence-Based Health Care, Department of Medical Research, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.; Division of General Surgery, Department of Surgery, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.; Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan.
Pokaż więcej
Źródło :
Pharmacotherapy [Pharmacotherapy] 2018 Nov; Vol. 38 (11), pp. 1106-1119. Date of Electronic Publication: 2018 Oct 17.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Gout/*drug therapy
Hyperuricemia/*drug therapy
Thioglycolates/*administration & dosage
Thioglycolates/*therapeutic use
Triazoles/*administration & dosage
Triazoles/*therapeutic use
Uricosuric Agents/*administration & dosage
Uricosuric Agents/*therapeutic use
Gout/complications ; Humans ; Hyperuricemia/etiology ; Randomized Controlled Trials as Topic ; Thioglycolates/adverse effects ; Triazoles/adverse effects ; Uricosuric Agents/adverse effects
Czasopismo naukowe
Tytuł :
2020 American College of Rheumatology Guideline for the Management of Gout.
Autorzy :
FitzGerald JD; University of California, Los Angeles and VA Greater Los Angeles Health Care System, Los Angeles, California.
Dalbeth N; University of Auckland, Auckland, New Zealand.
Mikuls T; University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska.
Brignardello-Petersen R; McMaster University, Hamilton, Ontario, Canada.
Guyatt G; McMaster University, Hamilton, Ontario, Canada.
Abeles AM; New York University School of Medicine, New York City, New York.
Gelber AC; Johns Hopkins University, Baltimore, Maryland.
Harrold LR; University of Massachusetts Medical School, Worcester Massachusetts, and Corrona, Waltham, Massachusetts.
Khanna D; University of Michigan, Ann Arbor.
King C; North Mississippi Medical Center, Tupelo.
Levy G; Kaiser Permanente, Downey, California.
Libbey C; Boston University School of Medicine, Boston, Massachusetts.
Mount D; VA Boston Healthcare System, Boston, Massachusetts.
Pillinger MH; New York University School of Medicine, New York City, New York.
Rosenthal A; Medical College of Wisconsin, Milwaukee.
Singh JA; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham.
Sims JE; Atlanta, Georgia.
Smith BJ; Florida State University College of Medicine School of Physician Assistant Practice, Tallahassee.
Wenger NS; University of California, Los Angeles.
Bae SS; University of California, Los Angeles.
Danve A; Yale University, New Haven, Connecticut.
Khanna PP; University of Michigan, VA Ann Arbor Healthcare System, Ann Arbor.
Kim SC; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Lenert A; University of Kentucky, Lexington.
Poon S; US Department of Veterans Affairs, Manchester, New Hampshire.
Qasim A; McMaster University, Hamilton, Ontario, Canada.
Sehra ST; Mount Auburn Hospital, Cambridge, Massachusetts.
Sharma TSK; Allegheny Health Network, Pittsburgh, Pennsylvania.
Toprover M; New York University School of Medicine, New York City, New York.
Turgunbaev M; American College of Rheumatology, Atlanta, Georgia.
Zeng L; McMaster University, Hamilton, Ontario, Canada.
Zhang MA; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Turner AS; American College of Rheumatology, Atlanta, Georgia.
Neogi T; Boston University School of Medicine, Boston, Massachusetts.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2020 Jun; Vol. 72 (6), pp. 744-760. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Gout/*therapy
Uricosuric Agents/*administration & dosage
Disease Management ; Healthy Lifestyle ; Humans ; Symptom Flare Up
Czasopismo naukowe
Tytuł :
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
Autorzy :
Smith WB; Volunteer Research Group, University of TN Medical Center, 1928 Alcoa Highway, Suite 107, Knoxville, TN, 37920, USA. .
Hall J; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Berg JK; DaVita Clinical Research, 825 S. 8th Street, Suite 300, Minneapolis, MN, 55404, USA.
Kazimir M; DaVita Clinical Research, Medical Plaza 1, 11750 West 2nd Place, Suite 300, Lakewood, CO, 80228, USA.
Yamamoto A; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Walker S; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Lee CA; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Shen Z; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Wilson DM; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Zhou D; Ardea Biosciences, Inc, 9390 Towne Centre Drive, San Diego, CA, 92121, USA.
Gillen M; AstraZeneca Pharmaceuticals LP, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.
Marbury TC; Orlando Clinical Research Center, 5055 South Orange Ave, Orlando, FL, 32809-3017, USA.
Pokaż więcej
Źródło :
Clinical drug investigation [Clin Drug Investig] 2018 Aug; Vol. 38 (8), pp. 703-713.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Organic Anion Transporters/*metabolism
Organic Cation Transport Proteins/*metabolism
Renal Insufficiency/*drug therapy
Renal Insufficiency/*metabolism
Uric Acid/*metabolism
Uricosuric Agents/*metabolism
Uricosuric Agents/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Humans ; Kidney/drug effects ; Kidney/metabolism ; Male ; Middle Aged ; Organic Anion Transporters/antagonists & inhibitors ; Organic Cation Transport Proteins/antagonists & inhibitors ; Uric Acid/antagonists & inhibitors ; Uricosuric Agents/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies